SNU-182細(xì)胞

細(xì)胞形態(tài)： 上皮樣

生長狀態(tài)： 貼壁生長

數(shù)量： 大量

年限： grade III/IV

是否是腫瘤細(xì)胞： 1

物種來源： 人

ATCC Number： CRL-2235?

相關(guān)**： 肝癌

器官來源： 肝

運輸方式： 凍存運輸

Designations: SNU-182

Depositors: J Park

SNU-182細(xì)胞Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ]

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: liver

Tumor Stage: grade III/IV

Disease: hepatocellular carcinoma

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. SNU-182細(xì)胞The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995).

Antigen Expression: Blood Type O; Rh +

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 10,12

D13S317: 11,14

D16S539: 11,13

D5S818: 11,12

D7S820: 11

THO1: 9

TPOX: 8,11

vWA: 17

Cytogenetic Analysis: SNU-182細(xì)胞aneuploid; modal number = 70

Age: 24 years *****

Gender: male

Ethnicity: Asian

Comments: SNU-182 was derived in 1989 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient prior to cytotoxic therapy.

Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat inactivated fetal bovine serum.

After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum.

Grossly, the original tumor was single nodular.

Histologically, it was predominantly trabecular and minor acinar type.

The cultured cells contain a single nucleus.

Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.

HBV genomic RNA was not expressed.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: SNU-182細(xì)胞Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.

Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.

Preservation: Culture medium, 95%; DMSO, 5%

Doubling Time: 46 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080